BioMarin is the world leader in delivering therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. We target diseases that lack effective therapies and affect relatively small numbers of patients, many of whom are children. These conditions are often inherited, difficult to diagnose, progressively debilitating and have few, if any, treatment options. BioMarin will continue to focus on advancing therapies that are the first or best of their kind.
BioMarin's Commercial organization supports our global sales and marketing efforts around the world. Our global sales force continues to solidify the company's commercial presence in the United States and Europe and is rapidly growing in other regions, such as Latin America, the Middle East and Asia-Pacific.
At BioMarin, we aspire to lift the voice of the hemophilia community the same way they inspire us to keep researching and moving toward the exceptional with
Valid through: 2020-2-21